Search

Your search keyword '"Gordon, Michael S"' showing total 1,252 results

Search Constraints

Start Over You searched for: Author "Gordon, Michael S" Remove constraint Author: "Gordon, Michael S"
1,252 results on '"Gordon, Michael S"'

Search Results

1. Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial

2. Submillimeter-wavelength Polarimetry of IRC+10216

3. How Well Do We Know Our Own Conscious Experience? The Case of Human Echolocation

8. Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid TumorsDilpacimab in Patients with Advanced Solid Tumors

9. Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors

10. On the collisional disalignment of dust grains in illuminated and shaded regions of IC 63

11. Red Supergiants, Yellow Hypergiants, and Post-RSG Evolution

12. Exploring the Mass Loss Histories of the Red Supergiants

13. Continuing Care App for Probationers and Parolees with Substance Use Disorders

14. ALMA polarimetry measures magnetically aligned dust grains in the torus of NGC 1068

15. The Unexpected Spectrum of the Innermost Ejecta of the Red Hypergiant VY CMa

16. BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

17. Luminous and Variable Stars in NGC 2403 and M81

18. Thermal Emission in the Southwest Clump of VY CMa

21. A Tale of Two Impostors: SN2002kg and SN1954J in NGC 2403

22. Searching for Cool Dust: II. Infrared Imaging of the OH/IR Supergiants, NML Cyg, VX Sgr, S Per and the Normal Red Supergiants RS Per and T Per

23. The daily progress system - a recovery support tool to improve engagement and retention in outpatient substance use treatment.

24. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer

25. Massive Star Formation in the LMC. I. N159 and N160 Complexes

26. Luminous and Variable Stars in M31 and M33. IV. Luminous Blue Variables, Candidate LBVs, and the B[e] Supergiants; How to Tell Them Apart

27. Multiple Outflows in the Giant Eruption of a Massive Star

28. Luminous and Variable Stars in M31 and M33. III. The Yellow and Red Supergiants and Post-Red Supergiant Evolution

29. On the Social Traits of Luminous Blue Variables

30. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.

31. A New Luminous Blue Variable in M31

32. Final outcomes analysis of the cell product SQZ‐PBMC‐HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration.

33. Phase II clinical trial of nab‐paclitaxel plus cisplatin plus gemcitabine (NABPLAGEM) in patients with untreated advanced pancreatic cancer.

35. Submillimeter-wavelength Polarimetry of IRC+10216

36. Paclitaxel protein bound (A) plus gemcitabine (G) plus cisplatin (C) and hydroxychloroquine (HCQ) neoadjuvant therapy for localized pancreatic ductal adenocarcinoma (PDAC).

37. Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

38. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

39. The Atacama Cosmology Telescope: Cosmological parameters from three seasons of data

43. Approaches for creating comparable measures of alcohol use symptoms: Harmonization with eight studies of criminal justice populations

44. A Sample of Candidate Radio Stars in FIRST and SDSS

45. A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma.

46. 756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects with advanced solid tumors

47. 594 SQZ-PBMC-HPV-101: Increased overall survival in a subset of patients with recurrent, locally advanced, or metastatic HPV16+tumors treated with cell-based vaccine, SQZ-PBMC-HPV

48. 692 COMMANDER-001: safety data from a phase I/II dose escalation/expansion study of SQZ-eAPC-HPV, a cell-based mRNA therapeutic cancer vaccine for HPV16+ solid tumors

49. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors

Catalog

Books, media, physical & digital resources